Editorials

Off label prescribing in children

BMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7349.1290 (Published 01 June 2002) Cite this as: BMJ 2002;324:1290

A view from the United States

  1. William Banner Jr, medical director
  1. The Children's Hospital at Saint Francis, Tulsa, Oklahoma 74136 USA

    Primary care pp 1311, 1312, 1313

    Three papers in this issue, one from Germany and two from the Netherlands, highlight the problem of off label prescribing in children. 1 2 At first reading these manuscripts were a confusing “tower of Babel” for a reader from the United States, but the problem being discussed is all too familiar. In the United States the Food and Drug Administration has responsibility for the licensing process for all drugs. The term “approved” is used for a drug that has been deemed to have safety and efficacy for a particular disease process. Until recently, the drug need only to have been studied in the adult male population. Yet once a drug is approved it may be prescribed by a physician for any population or disease state desired. The term “off label” has been applied to describe the use of these drugs in either populations or disease states not listed as indicated in the package insert. While attempts have been made to use the term off label to imply recklessness in the medical malpractice arena, the American Academy of Pediatrics has …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe